Data from Composition and Functional State of T and NK Cells in the Extramedullary Myeloma Tumor Microenvironment

Read full text
Authors: Anjana Anilkumar Sithara, Veronika Kapustová, David Žihala, Ondrej Venglár, Daniel Bilek, Moutaz Helal, Mara John, Eva Radova, Lucie Broskevičová, Jan Vrána, Gabriela Havlova, Ludmila Muroňová
+20 more Tereza Popková, Jana Mihályová, Hana Plonková, Serafim Nenarokov, Kamlesh Kumar Bisht, Hongfang Wang, Helgi J. Van de Velde, Sandra Charvátová, Ivo Demel, Michal Kaščák, Milan Navratil, Martin Havel, Juli Bago, Michal Šimíček, Angela Riedel, Leo Rasche, Tereza Ševčíková, Ola Landgren, Roman Hajek, Tomas Jelínek
Cited by: 0

Abstract

Abstract Extramedullary multiple myeloma (EMM) is a high-risk feature of multiple myeloma associated with increased resistance to treatments, including modern immunotherapies, and shorter survival. The composition and functional state of immune cells within the EMM tumor microenvironment (TME) remain poorly understood. Using single-cell RNA sequencing, flow cytometry, and spatial transcriptomics, we revealed significant differences in the EMM TME compared with multiple myeloma bone marrow (BM). T and NK cells were verified as the most abundant immune subsets in the EMM TME. Compared with the BM counterparts, we found these tumors to have a significantly reduced effector–to–tumor cell ratio, a significantly lower number of CD4+ T cells, and an increased proportion of regulatory CD16− NK cells. We observed a high proportion of exhausted, tumor-reactive CD8+ T cells in roughly half of EMM tumors. Furthermore, we identified elevated expression of immune checkpoints, such as PD-1 on CD8+ T cells and KLRC1 (NKG2A) on CD16− NK cells. Significance: This study characterizes the TME in EMM lesions and paired BM from patients with multiple myeloma, revealing a high proportion of less cytotoxic CD16− NK cells in EMM tumors and suggesting that direct cell–cell interactions may underlie the CD8+ T-cell exhaustion observed in a subset of these tumors.

Fields of Study & Subjects

Multiple Myeloma Research and Treatments Cancer Immunotherapy and Biomarkers Immune Cell Function and Interaction

Publication details

Publication date
4 March 2026
Language
EN